Cytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics. Mercè Jordà, University of Miami
|
|
|
- Lawrence Rose
- 6 years ago
- Views:
Transcription
1 Cytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics Mercè Jordà, University of Miami
2 Mortality Lung cancer is the most frequent cause of cancer incidence and mortality worldwide. Decline in mortality for African American and white males Increase in mortality for African American and white females Source: North American Association of Central Cancer Registries (NAACCR), the National Cancer Institute (NCI), and the American Cancer Society. Journal of the National Cancer Institute, May 4, 2011.
3 Cytology of Lung Cancer Basis for diagnosis 70% of lung cancers are diagnosed by cytology Equivalent results to biopsy for Diagnostic Prognostic Predictive Thorac Surg Clin May 23(2): , 2013.
4 Cytology of Lung Cancer Sampling Methods Sputum Transthoracic (FNA) Transbronchial (FNA, BB, BW) Transesophageal (FNA) Effusion
5 Primary Lung Neoplasms: Classification WHO 1967, 1981, 1999 Based on histomorphology WHO 2004 Based on histomorphology, genetics and clinical information
6 Type Frequency 5-year survival NSCLC Adenocarcinoma Squamous Cell Large Cell 80 % 17% 15% 11% Small Cell 20 % 5%
7 Primary Lung Neoplasms: Classification International Multidisciplinary Classification International Association for the study of lung cancer (IASLC) American Thoracic Society (ATS) European Respiratory Society (ERS) Identification of prognostic and predictive factors Applies to resection specimens and Small biopsies-cytology samples J Thorac Oncol. 2011; 6:
8 Current treatment of Lung cancer is focus in personalized medicine based on histologic cell type and molecular status Arch Pathol Lab Med 2013, 137:
9 NSCLC: Target Therapy tyrosine kinase inhibitors (TKI) first-line therapy in patients with advanced lung adenocarcinoma with EGFR mutations adenocarcinomas with ALK rearrangements are responsive to crizotinib (AlK inhibitor). Patients with KRAS or BRAF mutation do not respond to TKI, ALKI Arch Pathol Lab Med 2013, 137:
10 NSCLC: Target Therapy patients with adenocarcinoma or NSCLC, not otherwise specified (NSCLC-NOS),are more responsive to pemetrexed than those squamous cell carcinoma squamous cell carcinoma is associated with life-threatening hemorrhage in patients treated with bevacizumab; therefore, it is contraindicated in lung cancer patients with this histology. Arch Pathol Lab Med 2013, 137:
11 International Multidisciplinary Classification, 2011 Based on histologic cell type and molecular status Recommendation: NSCLC be further classified into a more specific type, such as adenocarcinoma or squamous cell carcinoma, whenever possible (strong recommendation). NSCLC-NOS be used as little as possible, and we recommend it be applied only when a more specific diagnosis is not possible by morphology and/or special stains Arch Pathol Lab Med 2013, 137:
12 WHO, 2004 Adenocarcinoma Small Biopsy/Cytology Adenocarcinoma: Mixed Type,Acinar,Papillary, Solid Adenocarcinoma: (describe patterns present: Acinar, Papillary, Solid, Micro-papillary **) Bronchioloalveolar (non-mucinous)* Bronchioloalveolar (mucinous)* Fetal Mucinous (colloid) Signet ring Clear cell No counterpart Adenocarcinoma with lepidic pattern Mucinous adenocarcinoma Adenocarcinoma with fetal pattern Adenocarcinoma with colloid pattern Adenocarcinoma signet ring cell features Adenocarcinoma with clear cell features NSCLC, favor Adenocarcinoma** Morphologic patterns not present Positive TTF-1 * Eliminated in J Thorac Oncol. 2011; 6: Arch Pathol Lab Med 2013, 137: ** New in
13 Adenocarcinoma: Cytomorphology Cohesive groups: flat sheets or 3-dimensional cell balls pseudopapillary aggregates true papillae with central fibrovascular cores acinar structures drunken honeycomb Individual tumor cells are: basophilic cytoplasm : granular, foamy, translucent,vacuoles The nuclei are: eccentrically located chromatin: from granular to hyperchromatic macronucleoli
14 Small Biopsy/Cytology Adenocarcinoma Biopsy Gland Forming Micropapillary Lepidic growth Mucinous diff. Colloid Signet-ring Clear cell Cytology
15 WHO 2004 Bronchoalveolar Carcinoma, non-mucinous Adenocarcinoma with lepidic pattern
16 WHO 2004 Bronchoalveolar Carcinoma, non-mucinous Adenocarcinoma with lepidic pattern
17 WHO 2004 Bronchoalveolar Carcinoma, non-mucinous Adenocarcinoma with lepidic pattern
18 WHO 2004 Bronchoalveolar Carcinoma, mucinous Mucinous Adenocarcinoma
19 WHO 2004 Bronchoalveolar Carcinoma, mucinous Mucinous Adenocarcinoma
20 WHO 2004 Bronchoalveolar Carcinoma, mucinous Mucinous Adenocarcinoma
21
22 WHO 2004 Adenocarcinoma Adenocarcinoma, micropapillary type
23
24 Use of Immunohistochemistry Use in cases lacking characteristics of adenocarcinoma or squamous cell carcinoma IHC can help in classifying NSCLC, nos into: NSCLC favor adenocarcinoma NSCLC favor squamous cell carcinoma Use only 2 markers to preserve material for molecular tests TTF-1: adenocarcinoma (or Mucin) P63 or p40: squamous cell carcinoma Cocktails of nuclear and cytoplasmic markers (TTF-1/cytokeratin 5/6 or p63/napsin A)
25 WHO 2004 No counterpart NSCLC, favor Adenocarcinoma
26 WHO 2004 No counterpart NSCLC, favor Adenocarcinoma TTF-1
27 Pleural Fluid: Adenocarcinoma
28 Pleural Fluid: Adenocarcinoma
29 Pleural Fluid: Adenocarcinoma from lung origin TTF-1 Cancer Cytopathol 96: , 2002
30 Squamous Cell Carcinoma Squamous cell carcinoma Papillary Clear cell Small cell Basaloid WHO, 2004 No counterpart Small Biopsy/Cytology Squamous cell carcinoma Papillary Clear cell Small cell Basaloid NSCLC, favor Squamous Cell Carcinoma Morphologic patterns not present Positive p40/p63 J Thorac Oncol. 2011; 6: Arch Pathol Lab Med 2013, 137:
31 Squamous cell carcinoma: Cytomorphology Cohesive groups: flat sheets, keratinizing changes, pearls, necrotic background Individual tumor cells: cytoplasm opaque or dense have round to ovoid to elongated contours with sharply defined cell borders, tadpole configurations The nuclei are: solitary, centrally situated, and hyperchromatic chromatin is very dense, homogeneous, pyknotic, nucleoli are not well developed.
32 WHO 2004 Squamous cell carcinoma Squamous cell carcinoma
33 WHO 2004 Squamous cell carcinoma Squamous cell carcinoma
34 WHO 2004 Squamous cell carcinoma Squamous cell carcinoma
35 Use of Immunohistochemistry Use in cases lacking characteristics of adenocarcinoma or squamous cell carcinoma IHC can help in classifying NSCLC, nos into: NSCLC favor adenocarcinoma NSCLC favor squamous cell carcinoma Use only 2 markers to preserve material for molecular tests TTF-1: adenocarcinoma (or Mucin) P63 or p40: squamous cell carcinoma Cocktails of nuclear and cytoplasmic markers (TTF-1/cytokeratin 5/6 or p63/napsin A)
36 WHO 2004 No counterpart NSCLC, favor Squamous Cell Carcinoma
37 WHO 2004 No counterpart NSCLC, favor Squamous Cell Carcinoma p63 Cancer Cytopathology 117 (1): 46-50, 2009.
38 WHO 2004 No counterpart NSCLC, favor Squamous Cell Carcinoma
39 WHO 2004 No counterpart NSCLC, favor Squamous Cell Carcinoma p40
40 WHO 2004 NSCLC, nos NSCLC, nos
41 p63
42 Small cell carcinoma WHO, 2004 Small cell carcinoma Small Biopsy/Cytology Small cell carcinoma Large cell Neuroendocrine NSCLC with NE morphology (Positive NE markers) Large cell Neuroendocrine with NE morphology NSCLC with NE morphology (negative NE markers) J Thorac Oncol. 2011; 6: Arch Pathol Lab Med 2013, 137:
43 Incidence Small cell Carcinoma 20% Non-small cell carcinoma 80%
44 Small Cell Carcinoma Cytomorphology Isolated small cells / small groups Crushing artifact Nuclear molding Cellular fragmentation Tumor necrosis
45 WHO 2004 Small Cell Carcinoma Small Cell Carcinoma
46 WHO 2004 Small Cell Carcinoma Small Cell Carcinoma PanKeratin
47 WHO 2004 Small Cell Carcinoma Small Cell Carcinoma
48 WHO 2004 Small Cell Carcinoma Small Cell Carcinoma PanKeratin
49 WHO 2004 Small Cell Carcinoma Small Cell Carcinoma TTF-1
50 WHO 2004 Small Cell Carcinoma Small Cell Carcinoma
51 WHO 2004 Small Cell Carcinoma Small Cell Carcinoma Chromogranin
52 WHO 2004 Large cell NE Carcinoma NSCLC with NE morphology (Positive NE markers)
53 WHO 2004 Large cell NE Carcinoma NSCLC with NE morphology (Positive NE markers) Chromogranin
54
55
56 Large Cell Carcinoma WHO, 2004 Large cell carcinoma Small Biopsy/Cytology Non-small cell carcinoma, nos J Thorac Oncol. 2011; 6: Arch Pathol Lab Med 2013, 137:
57 Large Cell Carcinoma: Cytomorphology No squamous or glandular differentiation Isolated cells Pleomorphic nuclei Macronucleoli Binucleation
58 WHO 2004 Large Cell Carcinoma Non-small cell carcinoma, NOS
59 Adenosquamous Carcinoma Adenosquamous Carcinoma WHO, 2004 Small Biopsy/Cytology Non-small cell carcinoma with squamous cell and adenocarcinoma patterns No counterpart J Thorac Oncol. 2011; 6: Arch Pathol Lab Med 2013, 137: Non-small cell carcinoma, NOS with IHC favoring both squamous and adenocarcinoma patterns
60 Sarcomatoid Carcinoma WHO, 2004 Small cell carcinoma Sarcomatoid Carcinoma NSCLC with spindle and or giant cell morphology (with or without adeno or squamous component)
61 Arch Pathol Lab Med 2013, 137:
62 NSCLC Prognostic and Predictive Biomarkers EGFR mutation: 15% of Caucasians 30% of Asians EGFR high copy number 40% Caucasians (FISH,IHC) KRAS mutation: 25% EML4-ALK translocation: 6% BRAF VEGF C-met P13k HER2 ROS1
63 NSCLC: Target Therapy tyrosine kinase inhibitors (TKI) first-line therapy in patients with advanced lung adenocarcinoma with EGFR mutations adenocarcinomas with ALK rearrangements are responsive to crizotinib (AlK inhibitor). Patients with KRAS or BRAF mutation do not respond to TKI, ALKI Arch Pathol Lab Med 2013, 137:
64
65
66
67 SDC4 ROS1 fusion identified in a patient with NSCLC who responded to crizotinib treatment. Davies K D et al. Clin Cancer Res 2012;18: by American Association for Cancer Research
68
LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
Ascitic Fluid and Use of Immunocytochemistry. Mercè Jordà, University of Miami
Ascitic Fluid and Use of Immunocytochemistry Mercè Jordà, University of Miami Is It Malignant? Yes? No Ascitic Fluid Cytomorphologic Useful Findings Tight clusters with smooth borders Cellular and nuclear
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
Disclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
Impact of immunostaining of pulmonary and mediastinal cytology
Impact of immunostaining of pulmonary and mediastinal cytology Harman Sekhon MD, PhD Director of Cytopathology Head of Ottawa-site Ontario Tumour Bank June 20, 2014 Disclaimer Pfizer: Honorarium-Advisory
Non-Small Cell Lung Carcinoma - Myers
Role of Routine Histology and Special Testing in Managing Patients with Non- Small Cell Lung Carcinoma Jeffrey L. Myers, M.D. A. James French Professor Director, Anatomic Pathology & MLabs University of
Lung Neoplasia II Resection specimens Pathobasic. Lukas Bubendorf Pathology
Lung Neoplasia II Resection specimens Pathobasic Lukas Bubendorf Pathology Agenda Preneoplastic lesions Histological subtypes of lung cancer Histological patterns of AC Cells of origin and characteristic
Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק
Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק 26.06.09 Lecture outlines WHO histological classification Macro/Micro assessment Early diagnosis Minimal pathology Main subtypes SCC, AdCa, LCLC
Diagnosis of lung cancer. Diagnosis Subtyping. Morphologic features Approach to small samples
Lung Cytology Lung Cytology Pınar Fırat,MD,MIAC Diagnosis of lung cancer Detection of infections Evaluation of interstitial diseases Morphologic features Approach to small samples Lung Cancer Second most
EBUS-TBNA Diagnosis and Staging of Lung Cancer
EBUS-TBNA Diagnosis and Staging of Lung Cancer Nirag Jhala MD, MIAC Professor of Pathology and Lab Med. Director of Anatomic Pathology and Cytopathology Lewis Katz School of Medicine@ Temple University
Steering Committee. Waiting on photo. Paul A. Bunn, Jr., MD Kavita Garg, MD Kim Geisinger, MD Fred R. Hirsch, Gregory Riely, MD, PhD.
Steering Committee Paul A. Bunn, Jr., MD Kavita Garg, MD Kim Geisinger, MD Fred R. Hirsch, Gregory Riely, MD, PhD MD, PhD Waiting on photo Paul Van Schil, MD, PhD William D. Travis, MD Ming-Sound Tsao,
Presentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98
Presentation material is for education purposes only. All rights reserved. 2011 URMC Radiology Page 1 of 98 Radiology / Pathology Conference February 2011 Brooke Koltz, Cytopathology Resident Presentation
Difficult Diagnoses and Controversial Entities in Neoplastic Lung
Difficult Diagnoses and Controversial Entities in Neoplastic Lung Lynette M. Sholl, M.D. Associate Pathologist, Brigham and Women s Hospital Chief, Pulmonary Pathology Service Associate Professor, Harvard
Lung/Thoracic Neoplasms. Manish Powari
Lung/Thoracic Neoplasms Manish Powari Biopsy Techniques in Lung cancer diagnosis Decreased cellularity and architecture; thereby influencing subtyping Thoracotomy, resection VATS biopsy/resection L.node
Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination
Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:
Problem 1: Differential of Neuroendocrine Carcinoma 3/23/2017. Disclosure of Relevant Financial Relationships
Differential of Neuroendocrine Carcinoma Alain C. Borczuk,MD Weill Cornell Medicine Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control
5/1/2009. Squamous Dysplasia/CIS AAH DIPNECH. Adenocarcinoma
Pathological Assessment of Diagnostic Specimens Keith Kerr Department of Pathology Aberdeen University Medical School Aberdeen Royal Infirmary Foresterhill, Aberdeen, Scotland, UK Tumours of the Lung:
Respiratory Tract Cytology
Respiratory Tract Cytology 40 th European Congress of Cytology Liverpool, UK Momin T. Siddiqui M.D. Professor of Pathology and Laboratory Medicine Director of Cytopathology Emory University Hospital, Atlanta,
and management of lung cancer Maureen F. Zakowski, M.D. Memorial Sloan-Kettering Cancer Center
The new role of cytology in the diagnosis and management of lung cancer Maureen F. Zakowski, M.D. Memorial Sloan-Kettering Cancer Center Outline Role of cytology in the diagnosis of lung cancer Non-small
What is New in the 2015 WHO Lung Cancer Classification? Zhaolin Xu, MD, FRCPC, FCAP
What is New in the 2015 WHO Lung Cancer Classification? Zhaolin Xu, MD, FRCPC, FCAP Professor, Dept of Pathology, Dalhousie University, Canada Pulmonary Pathologist and Cytopathologist, QEII HSC Senior
Pancreatic Cytopathology: The Solid Neoplasms
Pancreatic Cytopathology: The Solid Neoplasms Syed Z. Ali, M.D. Professor of Pathology and Radiology Director of Cytopathology The Johns Hopkins Hospital Baltimore, Maryland Pancreatic Cytopathology: Past,
Case 1. Slide 1 History: 65 year old male presents with bilateral pleural effusions, a 40 pack year smoking history and peripheral and hilar lung
Case 1. Slide 1 History: 65 year old male presents with bilateral pleural effusions, a 40 pack year smoking history and peripheral and hilar lung masses. Specimen shown is from a tap of the pleural effusion.
Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination
Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE:
Histology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
Histopathology of NSCLC, IHC markers and ptnm classification
ESMO Preceptorship on Non-Small Cell Lung Cancer November 15 th & 16 th 2017 Singapore Histopathology of NSCLC, IHC markers and ptnm classification Prof Keith M Kerr Department of Pathology, Aberdeen University
Pancreatitis: A Potential Pitfall in Endoscopic Ultrasound Guided Pancreatic FNA
Pancreatitis: A Potential Pitfall in Endoscopic Ultrasound Guided Pancreatic FNA Jack Yang, MD Department of Pathology, Medical University of South Carolina Objectives Understand the indication of EUS
The 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach
The 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach Dr. Carol Farver Director, Pulmonary Pathology Pathology and Laboratory Medicine Institute Objectives Discuss
Steering Committee. Waiting on photo. Paul A. Bunn, Jr., MD Kavita Garg, MD Kim Geisinger, MD Fred R. Hirsch, Gregory Riely, MD, PhD.
Steering Committee Paul A. Bunn, Jr., MD Kavita Garg, MD Kim Geisinger, MD Fred R. Hirsch, Gregory Riely, MD, PhD MD, PhD Waiting on photo Paul Van Schil, MD, PhD William D. Travis, MD Ming-Sound Tsao,
Historical Note 5/2/2017. Advances in Lung Cancer Cytohistology. Purpose of FNA in Patients with Lung Cancer
Advances in Lung Cancer Cytohistology Martha Bishop Pitman, M.D. Director, Cytopathology Massachusetts General Hospital Professor of Pathology Harvard Medical School Boston, MA Purpose of FNA in Patients
THE IASLC/ERS/ATS ADENOCARCINOMA CLASSIFICATION RATIONALE AND STRENGTHS
THE IASLC/ERS/ATS ADENOCARCINOMA CLASSIFICATION RATIONALE AND STRENGTHS PULMONARY PATHOLOGY SOCIETY USCAP, BALTIMORE, March 2, 2013 William D. Travis, M.D. Dept of Pathology, Memorial Sloan-Kettering Cancer
LUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS
LUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering Cancer Center New York, NY PULMONARY NE TUMORS CLASSIFICATION
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
Outline 11/2/2017. Pancreatic EUS-FNA general aspects. Cytomorphologic features of solid neoplasms/lesions of the pancreas
ENDOSCOPIC ULTRASOUND GUIDED-FINE NEEDLE ASPIRATION CYTOLOGY OF PANCREAS Khalid Amin M.D. Assistant Professor Department of Laboratory Medicine and Pathology University of Minnesota Outline Pancreatic
The role of the Pathologist in the diagnosis and biomarker profiling of Lung Cancer
The role of the Pathologist in the diagnosis and biomarker profiling of Lung Cancer Prof Keith M Kerr Department of Pathology Aberdeen University Medical School & Aberdeen Royal Infirmary, UK The management
Disclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)- Positive Pulmonary Adenocarcinoma. Joungho Han 1
Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)- Positive Pulmonary Adenocarcinoma In Ho Choi Dong Won Kim Sang Yoon Ha 1 Yoon-La Choi 1 Hee Jeong Lee 2 Joungho Han 1 Department
Update on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.
1 Our speaker for this program is Dr. Anja Roden, an associate professor of Laboratory Medicine and Pathology at Mayo Clinic as well as consultant in the Anatomic Pathology Laboratory and co-director of
Ground Glass Opacities
Ground Glass Opacities A pathologist s perspective Marie-Christine Aubry, M.D. Professor of Pathology Mayo Clinic Objectives Discuss the proposed new pathologic classification of adenocarcinoma with historical
LGM International, Inc.
Liqui-PREP TM Cytology Atlas Preface The following pictures are examples with descriptions of cytology slides processed with the Liqui-PREP TM System.. The descriptions are reviewed by Pathologists. It
Molecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
Cytology of Lung Carcinomas with Subtyping of Non-small Cell lung Carcinoma (NSCLC)
ISSN (Online): 39-764 Index Copernicus Value (3): 6.4 Impact Factor (4):.6 Cytology of Lung Carcinomas with Subtyping of Non-small Cell lung Carcinoma (NSCLC) Dr. Neeraj Dhameja, Dr. Hema Goyal, Dr. Ankush
A 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy.
November 2015 Case of the Month A 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy. Contributed by: Rasha Salama, M.D., IU Department of Pathology and Laboratory Medicine
Thyroid follicular neoplasms in cytology. Ulrika Klopčič Institute of Oncology, Department of Cytopathology, Ljubljana, Slovenia
Thyroid follicular neoplasms in cytology Ulrika Klopčič Institute of Oncology, Department of Cytopathology, Ljubljana, Slovenia Lecture overview importance of FNAB in assessing thyroid lesions follicular
Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification
Review Article Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification Swaroop Revannasiddaiah 1, Priyanka Thakur 2, Bhaskar Bhardwaj
SELECTED DILEMMAS IN RESPIRATORY CYTOPATHOLOGY (2 CASES)
SELECTED DILEMMAS IN RESPIRATORY CYTOPATHOLOGY (2 CASES) Dr. Mariamma Joseph Professor of Pathology Division Head Cytopathology Department of Pathology and Laboratory Medicine LHSC and Western University
Case 4 Diagnosis 2/21/2011 TGB
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
Case year old female presented with asymmetric enlargement of the left lobe of the thyroid
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
IASLC 2011/WHO 2015 CLASSIFICATION OF LUNG ADENOCARCINOMAS
Serban Negoita Dylan Holt Marsha Dunn IASLC 2011/WHO 2015 CLASSIFICATION OF LUNG ADENOCARCINOMAS DEMOGRAPHIC PATTERNS, TRENDS, AND IMPLICATIONS FOR CANCER SURVEILLANCE Outline Relevance of lung adenocarcinoma
Neuroendocrine Lung Tumors Myers
Diagnosis and Classification of Neuroendocrine Lung Tumors Jeffrey L. Myers, M.D. A. James French Professor Director, Anatomic Pathology & MLabs University of Michigan, Ann Arbor, MI myerjeff@umich.edu
Lung tumors & pleural lesions
Lung tumors & pleural lesions A brief introduction 95% of lung tumors are carcinomas Among the remaining 5%, we will discuss: -Hamartoma the most common benign lung tumor spherical, coin lesion on x-rays
FNA of Thyroid. Toward a Uniform Terminology With Management Guidelines. NCI NCI Thyroid FNA State of the Science Conference
FNA of Thyroid NCI NCI Thyroid FNA State of the Science Conference Toward a Uniform Terminology With Management Guidelines Thyroid Thyroid FNA Cytomorphology NCI Thyroid FNA State of the Science Conference
Lung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP
Lung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP Professor, Dept of Pathology, Dalhousie University Pulmonary Pathologist and Cytopathologist, QEII HSC Senior Scientist, Beatrice Hunter Cancer
YOUR LUNG CANCER PATHOLOGY REPORT
UNDERSTANDING SERIES YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...2 The Basics...3 Sections of a Pathology Report...6
Applying Genomics to Cancer 21 st September The Frequency of EGFR mutations in Lung Adenocarcinoma: The Cardiff Experience
Applying Genomics to Cancer 21 st September 2015 The Frequency of EGFR mutations in Lung Adenocarcinoma: The Cardiff Experience Aled Daniels R Butler, R Attanoos, H Davies University Hospital of Wales
The new international multidisciplinary lung adenocarcinoma
Eur Respir J 2011; 38: 239 243 DOI: 10.1183/09031936.00026711 CopyrightßERS 2011 EDITORIAL Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification W.D. Travis*,"",
Evolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
Primary enteric adenocarcinoma with predominantly signet ring features of the lung: A case report with clinicopathological and molecular findings
CASE REPORT Primary enteric adenocarcinoma with predominantly signet ring features of the lung: A case report with clinicopathological and molecular findings Makoto Nagashima 1, Ayako Moriyama 1, Yasuo
Thyroid Nodules: Understanding FNA Cytology (The Bethesda System for Reporting of Thyroid Cytopathology) Shamlal Mangray, MB, BS
Thyroid Nodules: Understanding FNA Cytology (The Bethesda System for Reporting of Thyroid Cytopathology) Shamlal Mangray, MB, BS Attending Pathologist Rhode Island Hospital, Providence, RI DISCLOSURE:
Classification of non-small cell lung carcinomas (NSCLC)
Classification of non-small cell lung carcinomas (NSCLC) 1. NordiQC Conference on Standardization in Applied Immunohistochemistry 4-7 June 2013 Birgit Guldhammer Skov, MD. DMeSci, Dept. Of Pathology, Rigshospitalet,
CYTOPATHOLOGIC AND MOLECULAR DIAGNOSTIC ISSUES IN LUNG CYTOPATHOLOGY
COMPANION MEETING Four Ps of Pulmonary Cytopathology: Procedural, Predictive, Personalized and Participatory CYTOPATHOLOGIC AND MOLECULAR DIAGNOSTIC ISSUES IN LUNG CYTOPATHOLOGY Prof. Fernando Schmitt
Key Words: napsin-a; TTF-1; p63; cytology; lung cancer. Ann Arbor, Michigan. School, Ann Arbor, Michigan
The Application and Diagnostic Utility of Immunocytochemistry on Direct Smears in the Diagnosis of Pulmonary Adenocarcinoma and Squamous Cell Carcinoma Michael H. Roh, M.D., Ph.D., 1{ Lindsay Schmidt,
UPDATES IN THE SURGICAL PATHOLOGY OF LUNG CANCER. Four Ps of Pulmonary Cytopathology: Procedural, Predictive, Personalized and Participatory
UPDATES IN THE SURGICAL PATHOLOGY OF LUNG CANCER travisw@mskcc.org Four Ps of Pulmonary Cytopathology: Procedural, Predictive, Personalized and Participatory American Society of Cytopathology Companion
ARTHUR PURDY STOUT SOCIETY COMPANION MEETING: DIFFICULT NEW DIFFERENTIAL DIAGNOSES IN PROSTATE PATHOLOGY. Jonathan I. Epstein.
1 ARTHUR PURDY STOUT SOCIETY COMPANION MEETING: DIFFICULT NEW DIFFERENTIAL DIAGNOSES IN PROSTATE PATHOLOGY Jonathan I. Epstein Professor Pathology, Urology, Oncology The Reinhard Professor of Urological
Neuroendocrine neoplasms of the lung
Neuroendocrine neoplasms of the lung M Papotti, L Righi, & M Volante University of Turin at San Luigi Hospital TORINO NETs OF THE LUNG Menu - Spectrum of NE lung tumors - CARCINOID TUMORS - SCLC /LCNEC
Medullary Thyroid Carcinoma. This case was provided by Treant Hospital, Bethesda, Hoogeveen, The Netherlands
Medullary Thyroid Carcinoma This case was provided by Treant Hospital, Bethesda, Hoogeveen, The Netherlands ADS-01504 Rev. 001 2016 Hologic, Inc. All rights reserved. Overview Medullary Thyroid Carcinoma
Case 3 - GYN. History: 66 year old, routine Pap test. Dr. Stelow
Case 3 - GYN History: 66 year old, routine Pap test Dr. Stelow Case 3 66 year year old woman Routine Pap Test Cytologic Features 3 dimensional clusters of cells with small to moderate amount of
Diagnostic & Predictive Immunohistochemistry in Lung Carcinomas
Diagnostic & Predictive Immunohistochemistry in Lung Carcinomas Lynette M. Sholl, M.D. Associate Pathologist, Brigham and Women s Hospital Associate Professor, Harvard Medical School Boston, MA Disclosures
Hyperchromatic Crowded Groups: What is Your Diagnosis? Session 3000
Hyperchromatic Crowded Groups: What is Your Diagnosis? Session 3000 Thomas A. Bonfiglio, M.D. Professor Emeritus, Pathology and Laboratory Medicine University of Rochester Disclosures In the past 12 months,
What s New in Pathology of Genitourinary Tumors. Jiaoti Huang, MD, PhD Department of Pathology Duke University School of Medicine
What s New in Pathology of Genitourinary Tumors Jiaoti Huang, MD, PhD Department of Pathology Duke University School of Medicine Kidney Tumors Multilocular cystic renal neoplasm of low malignant potential
ACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016
Diagnosing Mesothelioma in Limited Tissue Samples Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016 Sanja Dacic, MD, PhD University of Pittsburgh ACCME/Disclosures GENERAL RULES
Lin Yang 1, Yun Ling 1, Lei Guo 1, Di Ma 2, Xuemin Xue 1, Bingning Wang 1, Junling Li 2, Jianming Ying 1. Original Article.
Original Article Detection of ALK translocation in non-small cell lung carcinoma (NSCLC) and its clinicopathological significance using the Ventana immunohistochemical staining method: a single-center
The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer
The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer Nathan A. Pennell, M.D., Ph.D. Assistant Professor Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute www.cancergrace.org
MOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE
25 th IAP-Arab Division Conference 07-09 November 2013, Amman, Jordan MOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE Fouad Al Dayel, MD, FRCPA, FRCPath Professor and Chairman Department
International association for the study of lung cancer/american thoracic society/european respiratory
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. William Travis, Elisabeth
Tumors of the Lungs and Pleura
5 Tumors of the Lungs and Pleura Saul Suster and Cesar Moran Introduction Carcinoma of the lung is a common malignant tumor. Histological typing of lung tumors has long been a source of controversy in
Early-stage locally advanced non-small cell lung cancer (NSCLC) Clinical Case Discussion
Early-stage locally advanced non-small cell lung cancer (NSCLC) Clinical Case Discussion Pieter Postmus The Clatterbridge Cancer Centre Liverpool Heart and Chest Hospital Liverpool, United Kingdom 1 2
Prepared By Jocelyn Palao and Layla Faqih
Prepared By Jocelyn Palao and Layla Faqih The structure of the suspected atypical cell should always be compared to the structure of other similar, benign, cells which are present in the smears. The diagnosis
DIAGNOSTIC DILEMMA. Case Reports Clinical history. Materials and Methods
DIAGNOSTIC DILEMMA A Metastatic Renal Carcinoid Tumor Presenting as Breast Mass: A Diagnostic Dilemma Farnaz Hasteh, M.D., 1 Robert Pu, M.D., Ph.D., 2 and Claire W. Michael, M.D. 2 * We present clinicopathological
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
Advances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
Effusion Cytology: Diagnostic Challenges
Effusion Cytology: Diagnostic Challenges Tarik M. Elsheikh, MD Professor and Medical Director, Anatomic Pathology Cleveland Clinic Outside Consult Case 45 year old woman, presented with nausea, dyspnea,
The lung adenocarcinoma guidelines: what to be considered by surgeons
Review Article The lung adenocarcinoma guidelines: what to be considered by surgeons Rodrigo A. S. Sardenberg 1, Evandro Sobroza Mello 1, Riad N. Younes 2 1 Hospital Alemão Oswaldo Cruz, São Paulo, Brazil;
Personalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE. Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, CT
2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, CT 2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE AUTHORS : PROSTATE CHAPTER
Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells
2013 California Society of Pathologists 66 th Annual Meeting San Francisco, CA Atypical Glandular Cells to Early Invasive Adenocarcinoma: Cervical Cytology and Histology Christina S. Kong, MD Associate
Fast Facts: Non-Small-Cell Lung Cancer
Fast Facts Fast Facts: Non-Small-Cell Lung Cancer Mary O Brien MD FRCP Consultant Medical Oncologist The Royal Marsden NHS Foundation Trust London, UK Benjamin Besse MD PhD Thoracic Cancer Unit, Head Department
Minimally invasive adenocarcinoma. 5mm or less = microinvasion No necrosis No lymphatic or pleural invasion No spread through air-spaces (STAS)
Minimally invasive adenocarcinoma 5mm or less = microinvasion No necrosis No lymphatic or pleural invasion No spread through air-spaces (STAS) 2b lepidic acinar 2c papillary micropapillary solid 2d cribriform
The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements
Page 1 Contents 1.1. Registration... 2 1.2. Patient Characteristics... 3 1.3. Laboratory Values at Diagnosis... 5 1.4. Lung Cancers with Multiple Lesions... 6 1.5. Primary Tumour Description... 10 1.6.
Case Studies. Ravi Salgia, MD, PhD
Case Studies Ravi Salgia, MD, PhD Professor and Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Associate Director for Clinical Sciences Research City of Hope 04-21-2018 Objectives
EBUS-FNAB: HOW TO OPTIMIZE YOUR CYTOLOGY SAMPLES, LHSC EXPERIENCE. Dr. Mariamma Joseph Division Head of Cytopathology LHSC and Western University
EBUS-FNAB: HOW TO OPTIMIZE YOUR CYTOLOGY SAMPLES, LHSC EXPERIENCE Dr. Mariamma Joseph Division Head of Cytopathology LHSC and Western University Objectives Brief overview of EBUS-FNA Strategies to optimize
Thyroid pathology Practical part
Thyroid pathology Practical part My Algorithm After a good macroscopy and a microscopic overview of the lesion, I especially look at the capsule and the thyroid just above and just beneath the capsule.
Evening Specialty Conference: Cytopathology
: Cytopathology N. Paul Ohori, M.D. University of Pittsburgh Medical Center Disclosure of Relevant Financial Relationships Disclosure of Relevant Financial Relationships USCAP requires that all planners
Case Report Tumor-to-Tumor Metastasis: Lung Carcinoma Metastasizing to Thyroid Neoplasms
Hindawi Publishing Corporation Volume 2015, Article ID 153932, 5 pages http://dx.doi.org/10.1155/2015/153932 Case Report Tumor-to-Tumor Metastasis: Lung Carcinoma Metastasizing to Thyroid Neoplasms Shiuan-Li
Objectives 04/26/2018. Lung Cytology and Histology: Getting What You Need from Small Samples
Lung Cytology and Histology: Getting What You Need from Small Samples Dr. Jennifer Brainard Section Head Cytopathology Cleveland Clinic Objectives Define the current required molecular testing for NSCLC
Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers
Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers Program 7:15 7:40 Translocations as predictive biomarkers in lung cancer: Overview Mari Mino Kenudson, MD 7:40 8:05 Translocation
Reparatory system 18 lectures Heyam Awad
Reparatory system 18 lectures 8-10 Heyam Awad These lectures cover the following topics 1. Diffuse hemorrhagic syndromes 2. Lung tumors important: theses slides are your study source for these lectures.
8/22/2016. Major risk factors for the development of lung cancer are: Outline
Carcinomas of the Lung: Changes in Staging, Adenocarcinoma Classification and Genetics Grace Y. Lin, M.D., Ph.D. Outline Background Staging of Lung Cancer: Review of the 2010 7 th Edition of the AJCC Cancer
3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Lung Cancer T STAGE OUTLINE SURVIVAL ACCORDING TO SIZE ONLY
Pathologic Staging Updates in Lung Cancer Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME
SQUAMOUS CELLS: Atypical squamous cells (ASC) - of undetermined significance (ASC-US) - cannot exclude HSIL (ASC-H)
SQUAMOUS CELLS: Atypical squamous cells (ASC) - of undetermined significance (ASC-US) - cannot exclude HSIL (ASC-H) ASC refers to cytologic changes suggestive of SIL, which are qualitativley or quantitatively